The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:1256-1259 September 20, 2007 Number 12
NextNext

Adjuvant Mitotane in Adrenocortical Carcinoma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Schteingart, D. E.
-Related Article
by Terzolo, M.
-PubMed Citation
To the Editor: On the basis of their analysis involving 177 patients with adrenocortical cancer from 55 centers, Terzolo et al. (June 7 issue)1 suggest that adjuvant mitotane therapy prolongs disease-free survival. This finding is important considering the poor outcome of this rare cancer.2 However, variations in management (heterogeneous follow-up among centers) and in tumor biology (molecular alterations3) suggest potential bias in this retrospective, multicenter study.

We previously reported findings from a study involving 202 patients from a single center. In our study, initiation of mitotane within 3 months after surgery improved overall survival among patients with cortisol-secreting tumors.4 . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.